非ST段抬高型急性冠脉综合征患者行PCI后应用替格瑞洛双联抗血小板治疗的远期疗效观察  

Long-term curative effect of ticagrelor dual anti-platelet therapy in patients with non-ST-segment elevation acute coronary syndromes after PCI

作　　者：付永波 朱冬梅 万翔[1] 胡绍波 Fu Yongbo;Zhu Dongmei;Wan Xiang;Hu Shaobo(Department of Cardiovascular Medicine,First People's Hospital of Xiantao City,Yangtze University,Hubei Province,Xiantao 433000,China;不详)

机构地区：[1]长江大学附属仙桃市第一人民医院心血管内科,仙桃433000 [2]长江大学附属仙桃市第一人民医院内分泌科,仙桃433000

出　　处：《中国循证心血管医学杂志》2020年第9期1125-1128,共4页Chinese Journal of Evidence-Based Cardiovascular Medicine

摘　　要：目的探讨替格瑞洛用于非ST段抬高型急性冠脉综合征患者(NSTE-ACS)行经皮冠状动脉介入治疗(PCI)后的远期疗效及安全性。方法选择2015年1月至2016年1月于长江大学附属仙桃市第一人民医院确诊并行PCI的NSTE-ACS患者120例,随机分为对照组和观察组,每组各60例,观察组采用替格瑞洛双联抗血小板治疗,对照组采用氯吡格雷双联抗血小板治疗,两组患者均连续服药12个月,分别于术后12,24及36个月检测两组患者的血小板聚集率、主要不良心血管事件发生率、出血事件发生率及不良反应情况。结果两组患者入院即刻血小板聚集率无明显差异(P>0.05),术后双联抗血小板治疗12、24及36个月后观察组患者的血小板聚集率均明显低于对照组(P<0.05);术后12个月,两组患者的心血管不良事件发生率、出血事件发生率均无明显差异(P>0.05);术后24个月及36个月观察组患者的心血管不良事件发生率、出血事件发生率均明显低于对照组(P<0.05);随访过程中观察组不良反应发生率10.00%,对照组不良反应发生率8.33%,两组比较无明显差异(P>0.05)。结论NSTE-ACS患者行PCI后采用替格瑞洛双联抗血小板治疗方案能够有效抑制血小板聚集,降低远期心血管不良事件发生率及出血事件发生率,且不良反应发生率较低,安全性高。Objective To discuss the long-term curative effect and safety of ticagrelor in patients with non-ST-segment elevation acute coronary syndromes(NSTE-ACS)after percutaneous coronary intervention(PCI).Methods NSTE-ACS patients(n=120)undergone PCI were chosen from the First People’s Hospital of Xiantao City affiliated to Yangtze University from Jan.2015 to Jan.2016,and divided randomly into control group and observation group(each n=60).The observation group was treated with ticagrelor dual anti-platelet therapy(DAPT)and control group was treated with clopidogrel DAPT for 12 months.The platelet aggregation rate(PAR),incidence rate of major adverse cardiovascular events(MACE),incidence rate of bleeding events and adverse reactions were detected in 2 groups after PCI and DAPT respectively for 12,24 and 36 months.Results PAR had no significant difference between 2 groups immediately after hospitalization(P>0.05),and was significantly lower in observation group than that in control group after PCI and DAPT for 12,24 and 36 months(P<0.05).The incidence rates of MACE and bleeding events had no significant difference between 2 groups after PCI and DAPT for 12 months(P>0.05).The incidence rates of MACE and bleeding events were significantly lower in observation group than those in control group after PCI and DAPT for 24 and 36 months(P<0.05).The incidence rates of adverse reactions were 10.00%in observation group and 8.33%in control group(P>0.05)during follow-up period.Conclusion Ticagrelor DAPT can effectively inhibit PAR and reduce the incidence rates of MACE and bleeding events with lower incidence rates of adverse reactions and higher safety in NSTE-ACS patients undergone PCI.

关 键 词：替格瑞洛 非ST段抬高型急性冠脉综合征 经皮冠状动脉介入 

分 类 号：R541.4[医药卫生—心血管疾病]